Avi Mazaltov Net Worth

Avi Mazaltov biography

Avi Mazaltov serves as Global Head of Manufacturing and SciVac General Manager of the Company. Mr. Mazaltov has served as our Global Head of Manufacturing since May 2017. Mr. Mazaltov is an operations executive with broad experience across industries in defining, managing, and optimizing manufacturing and supply chain activities. Mr. Mazaltov joined VBI in 2017 from Omrix Biopharmaceuticals (a Johnson & Johnson company). At Omrix, Mr. Mazaltov was responsible for Biosurgery operations in Israel and was a member of the Biosurgery leadership team. Prior to joining Omrix, Mr. Mazaltov led the Operations and Infrastructures division of Alvarion Technologies. Prior to Alvarion, Mr. Mazaltov held various high-ranking operational roles at Teva Pharmaceuticals, including Director, Global Manufacturing and Plant Manager, Kfar Saba, where he managed a production facility with 1,000+ employees. Mr. Mazaltov holds a B.Sc. in Industrial Engineering from Ben Gurion University of the Negev, Israel.

How old is Avi Mazaltov?

Avi Mazaltov is 58, he's been the Global Head of Manufacturing and SciVac General Manager of VBI Vaccines since 2017. There are 9 older and 9 younger executives at VBI Vaccines. The oldest executive at VBI Vaccines Inc. is Michel Wilde, 70, who is the Independent Director.

What's Avi Mazaltov's mailing address?

Avi's mailing address filed with the SEC is C/O VBI VACCINES INC.,, 160 SECOND STREET, FLOOR 3, CAMBRIDGE, MA, 02142.

Insiders trading at VBI Vaccines

Over the last 8 years, insiders at VBI Vaccines have traded over $18,633,012 worth of VBI Vaccines stock and bought 55,142,222 units worth $66,770,591 . The most active insiders traders include Advisors Llcperceptive Life..., Tomer Kariv und Steven D Rubin. On average, VBI Vaccines executives and independent directors trade stock every 62 days with the average trade being worth of $130,457. The most recent stock trade was executed by Steven Gillis on 10 July 2023, trading 609,090 units of VBIV stock currently worth $1,004,999.

What does VBI Vaccines do?

vbi vaccines inc. (nasdaq: vbiv) is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. vbi’s evlp vaccine platform allows for the design of enveloped (“e”) virus-like particle (“vlp”) vaccines that closely mimic the target virus. the company’s lead evlp asset is a prophylactic cytomegalovirus (cmv) vaccine; vbi has initiated work for gmp manufacturing of its cmv candidate for use in formal preclinical and phase i trials. the company’s second platform is a thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. vbi has completed proof of concept thermostability studies on a number of vaccine and biologic targets. vbi is headquartered in cambridge, ma with research facilities in ottawa, canada.

VBI Vaccines executives and stock owners

VBI Vaccines executives and other stock owners filed with the SEC include:

• Jeffrey Baxter,
  President, Chief Executive Officer, Director
• Jeffery R. Baxter F.C.M.A., FCMA,
  Pres, CEO & Director
• Francisco Diaz-Mitoma,
  Chief Medical Officer
• David Anderson,
  Chief Scientific Officer
• Jeffrey R. Baxter F.C.M.A., FCMA,
  Pres, CEO & Director
• Steven Gillis,
  Independent Chairman of the Board
• Dr. Francisco Diaz-Mitoma FRCPC, M.D., Ph.D.,
  Chief Medical Officer
• Blaine Mckee,
  Independent Director
• Dr. David Evander Anderson,
  Chief Scientific Officer
• Joanne Cordeiro,
  Independent Director
• Michel Wilde,
  Independent Director
• Christopher McNulty,
  CFO & Head of Bus. Devel.
• Nicole Anderson,
  Investor Relations
• Damian Braga,
  Independent Director
• Avi Mazaltov,
  Global Head of Manufacturing and SciVac General Manager
• Nell Beattie,
  Chief Business Officer
• Christopher McNulty,
  Chief Financial Officer and Head of Business Development, Director
• Avi Mazaltov,
  Global Head of Manufacturing & GM of SciVac
• Nell Beattie,
  Chief Bus. Officer
• T. Adam Buckley,
  Sr. VP of Bus. Devel.
• Misha Nossov,
  Sr. VP of Market Access & Commercial
• Athena Kartsaklis,
  Sr. VP of Fin., Chief Compliance Officer & Principal Financial Officer
• Scott Requadt,
  Director
• Catherine Eckenswiller,
  Contracts and IP Counsel
• Sam Chawla,
  Director
• Egidio Nascimento,
  Chief Financial Officer
• Adam Logal,
  Director
• Jeff Baxter,
  CEO, President
• T. Adam Buckley,
  VP, Business Development
• Steven D Rubin,
  Director
• Advisors Llcperceptive Life...,
  
• Health, Inc. Opko,
  10% owner
• Tomer Kariv,
  Director
• Athena Kartsaklis,
  SVP Finance, CCO
• Vaughn B Himes,
  Director
• Linda Bain,
  Director
• John Robert Dillman,
  Chief Commercial Officer